Andrew S. Tasker
Publications by Year
Research Areas
Cancer Mechanisms and Therapy, Nitric Oxide and Endothelin Effects, Synthesis and biological activity, PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts(2006)283 cited
- → TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic Transformation(2011)228 cited
- → Systematic Study of the Glutathione (GSH) Reactivity ofN-Arylacrylamides: 1. Effects of Aryl Substitution(2015)150 cited
- → c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations(2007)137 cited
- → 2,4-Diarylpyrrolidine-3-carboxylic AcidsPotent ETA Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722(1996)110 cited
- → Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability(2014)104 cited
- → Design, Synthesis, and Biological Evaluation of Potent c-Met Inhibitors(2008)90 cited
- → Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 4. Side Chain Conformational Restriction Leads to ETB Selectivity(1999)90 cited
- → Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease(2014)85 cited
- → Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors(2006)83 cited